Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05438212 · ClinicalTrials.gov registry record · Phase 3

Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases

A Phase 3 study of Metastatic Malignant Neoplasm in the Brain, sponsored by NRG Oncology.

Active
Registry status
Phase 3
Development phase
237
Enrollment target
20
Study locations

NCT05438212: Active Phase 3 study of Metastatic Malignant Neoplasm in the Brain, sponsored by NRG Oncology.

NCT05438212 is a Phase 3 study of Metastatic Malignant Neoplasm in the Brain that is active but no longer recruiting, run by NRG Oncology. The registered enrollment target is 237 participants, above the 83-participant average among 43 other Metastatic Malignant Neoplasm in the Brain trials with a reported enrollment target (186% higher). The trial reports 20 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05438212, a Phase 3 study of Metastatic Malignant Neoplasm in the Brain, is active but no longer recruiting, sponsored by NRG Oncology.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
237 participants
Enrollment target
20
Study locations

Study Summary

This phase III trial compares the usual treatment of surgery after stereotactic radiosurgery (SRS) to receiving SRS before surgery in treating patients with cancer that has spread to the brain (brain metastases). Stereotactic radiosurgery is a type of radiation therapy that delivers a high dose of radiation to target tumors and minimizes effect on normal surrounding brain tissue. The combination of surgery and radiation may stop the tumor from growing for a few months or longer and may reduce symptoms of brain metastases. This study investigates whether treating with SRS before surgery may be better than SRS after surgery in reducing the possibility of the tumor coming back, reducing or preventing the cancer from spreading to other areas of the brain and reducing the risk of scarring on the brain from radiation.

Primary Outcome

Analysis for this endpoint will consist of testing the cause-specific hazard ratio in a Cox proportional hazards model.

Interventions

  • OTHER Quality-of-Life Assessment
  • OTHER Questionnaire Administration
  • RADIATION Stereotactic Radiosurgery
  • PROCEDURE Brain Surgery

Study Locations (20)

California

  • Kaiser Permanente-Anaheim - Anaheim
  • Sutter Auburn Faith Hospital - Auburn
  • Sutter Cancer Centers Radiation Oncology Services-Auburn - Auburn
  • Kaiser Permanente-Bellflower - Bellflower
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care - Irvine
  • Kaiser Permanente Los Angeles Medical Center - Los Angeles
  • Memorial Medical Center - Modesto
  • Kaiser Permanente-Ontario - Ontario
  • Saint Joseph Hospital - Orange - Orange
  • UC Irvine Health/Chao Family Comprehensive Cancer Center - Orange
  • Stanford Cancer Institute Palo Alto - Palo Alto
  • Sutter Cancer Centers Radiation Oncology Services-Roseville - Roseville
  • Sutter Roseville Medical Center - Roseville
  • Sutter Medical Center Sacramento - Sacramento
  • University of California Davis Comprehensive Cancer Center - Sacramento
  • California Pacific Medical Center-Pacific Campus - San Francisco
  • UCSF Medical Center-Parnassus - San Francisco

Arizona

  • Saint Joseph's Hospital and Medical Center - Phoenix
  • Banner University Medical Center - Tucson - Tucson
  • University of Arizona Cancer Center-North Campus - Tucson

Trial Details

FieldValue
Enrollment Target 237 participants
Start Date 2022-10-24
Est. Completion 2027-03-16
Phase Phase 3
NRG Oncology

64 total trials

What the registry record for NCT05438212 still lists

NCT05438212 is an interventional study that assigns participants to a tested intervention. The registered 237 participants enrollment target is mid-sized for trials with a published cap, above the 83-participant average among 43 other Metastatic Malignant Neoplasm in the Brain trials with a reported enrollment target (186% higher).

The record links to 1 condition, with Metastatic Malignant Neoplasm in the Brain appearing as the primary indexed condition, and to 4 interventions - of which Quality-of-Life Assessment is the first listed.

NCT05438212 names 20 study sites across 2 states, led by California, Arizona.

Frequently Asked Questions

What is clinical trial NCT05438212 about?

NCT05438212 is a clinical study titled "Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases". This phase III trial compares the usual treatment of surgery after stereotactic radiosurgery (SRS) to receiving SRS before surgery in treating patients with cancer that has spread to the brain (brain metastases). Stereotactic radiosurgery is a type of radiation therapy that delivers a high dose of r...

What is the current status of trial NCT05438212?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 237 participants. The study started on 2022-10-24. Estimated completion is 2027-03-16.

What conditions does trial NCT05438212 study?

This clinical trial studies the following conditions: Metastatic Malignant Neoplasm in the Brain.

What interventions are being tested in trial NCT05438212?

The interventions under investigation include: Quality-of-Life Assessment (OTHER), Questionnaire Administration (OTHER), Stereotactic Radiosurgery (RADIATION), Brain Surgery (PROCEDURE).

Who is sponsoring clinical trial NCT05438212?

This trial is sponsored by NRG Oncology, which has 64 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05438212 being conducted?

This trial has 20 study locations across Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Metastatic Malignant Neoplasm in the Brain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05438212's enrollment target sits among peer trials

237 4th of 43 higher than 40 of 43 other Metastatic Malignant Neoplasm in the Brain trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Metastatic Malignant Neoplasm in the Brain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05974176 · 237 participants · NA

    Considering Racial and Acculturation Stress in Addressing Trauma

  • NCT05012072 · 238 participants · NA

    Reducing Pregnancy Risks: The Mastery Lifestyle Intervention

  • NCT05400252 · 238 participants · NA

    Whole Health in VA Mental Health: Omnis Salutis

  • NCT06380517 · 238 participants · Phase 3

    Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05438212, the US trial registry maintained by the National Library of Medicine. NCT05438212 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.